NT 157 is primarily used in research settings for its ability to inhibit certain signaling pathways involved in cancer cell survival and proliferation. It targets insulin receptor substrates (IRS1 and IRS2), which play a role in tumor growth and resistance to therapy. This makes NT 157 a valuable tool in studies focused on overcoming drug resistance in cancers, particularly those dependent on insulin-like growth factor signaling. It has shown potential in enhancing the effectiveness of other anticancer agents by suppressing survival pathways in tumor cells. Researchers also explore its role in inducing apoptosis and reducing the viability of cancer cells in models of melanoma, breast cancer, and colorectal cancer. Due to its action on metabolic and growth signaling pathways, NT 157 is further investigated for effects beyond oncology, including aging and cellular stress responses. However, its use remains strictly experimental and confined to preclinical research.